Poolbeg Pharma
Clinical-stage biopharmaceutical, AI-led discovery
A clinical-stage biopharmaceutical company using AI and two decades of human challenge trial data to find drug targets faster.
About Poolbeg Pharma
Poolbeg Pharma is a clinical-stage biopharmaceutical company listed on the London Stock Exchange under the ticker POLB. Its core focus is transforming cancer immunotherapy, alongside programmes in obesity and infectious disease.
The company works to a partnering model: it advances high-value programmes that target large markets and unmet clinical need, then partners them for late-stage development and commercialisation rather than building that infrastructure itself.
What sets its discovery work apart is the data behind it. Poolbeg holds a private repository of clinical samples and data from human challenge trials, in which healthy volunteers are followed through infection, progression and recovery under controlled conditions. That gives longitudinal virology, biomarker and symptom data with matched baseline samples, the kind of dataset AI models rarely get access to.
Programmes
- POLB 001 · Cancer immunotherapy
- An oral preventative therapy for immunotherapy-induced Cytokine Release Syndrome, holding FDA Orphan Drug Designation. Preventing CRS could allow immunotherapies to be delivered in community hospitals instead of specialist cancer centres, widening patient access.
- Oral encapsulated GLP-1 · Obesity
- An oral formulation of a GLP-1 therapy using proprietary delivery technology, aimed at the large share of patients who discontinue injectable treatment and say they would prefer an oral alternative.
- AI discovery · Influenza and RSV
- Two discovery-stage programmes built on the human challenge trial repository. The influenza programme, run with CytoReason, has identified multiple novel drug targets. The RSV programme, run with OneThree Biotech, has mapped disease-relevant pathways and prioritised candidates that already carry Phase I clinical data for repositioning.
At a glance
- Listed on the London Stock Exchange (POLB)
- FDA Orphan Drug Designation for POLB 001
- 20+ years of human challenge trial data
- AI partners: CytoReason and OneThree Biotech